Protagonist Therapeutics, Inc. (PTGX) Stock Price & How to Invest

Last updated November 2026

Short answer

PTGX (Protagonist Therapeutics) is a commercial-stage biotech whose whole story runs through two partnered peptide drugs, both now FDA-approved: icotrokinra (marketed as ICOTYDE, licensed to Johnson & Johnson) and rusfertide (marketed as MIMRYLO, licensed to Takeda, approved in August 2026). You are buying a royalty-and-milestone engine on those two assets plus an early pipeline, so the thesis now lives or dies on launch uptake and partner economics rather than on Protagonist selling anything itself. Q3 2026 was the company's biggest quarter yet, with about $274 million of revenue and EPS of $3.07 against a $2.66 consensus, almost all from Takeda's MIMRYLO payments. As of November 20, 2026 the shares closed near $121.85, up about 40% year to date and 45% over one year, though down about 12% over the past month.

PTGX stock price

As of 2026-11-20, Protagonist Therapeutics, Inc. (PTGX) last closed at $121.40, up 42.2% over the past year. Over the past 52 weeks it has traded between $79.73 and $158.62.

PTGX last close
$121.40
1 day
-2.11%
1 month
-12.08%
1 year
+42.15%
52-week range
$79.73 to $158.62
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Protagonist Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.

PTGX key stats

At $121.40 on November 20, 2026, Protagonist Therapeutics, Inc. (PTGX) has a market cap of $7.9B and a P/E of 25.7 on trailing earnings (348.8 on forward earnings).

Market cap
$7.9B
P/E (trailing)
25.7
P/E (forward)
348.8
EPS (trailing 12 months)
$4.73
Price to book
7.3
Beta
1.22

Market cap, P/E and yield are measured at the $121.40 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Protagonist Therapeutics, Inc. (PTGX)?

The last two weeks for Protagonist Therapeutics, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • PTGX closed at $121.40 on November 20, 2026, down 7.3% over the past five trading days (from $130.95).

Protagonist Therapeutics, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Protagonist Therapeutics, Inc. (PTGX) do?

Protagonist Therapeutics is a Newark, California biotech that discovers oral and injectable peptide-based drugs and develops them mostly through large-pharma partners. Its two lead assets define the company: icotrokinra, an oral IL-23 receptor antagonist licensed to Johnson & Johnson and launched in the U.S. in March 2026 (branded ICOTYDE) for moderate-to-severe plaque psoriasis, and rusfertide, a once-weekly injectable hepcidin mimetic licensed to Takeda that the FDA approved in August 2026 as MIMRYLO for erythrocytosis in adults with polycythemia vera. ICOTYDE has since also been approved in China, Japan and the EU. Behind those, the pipeline includes an oral IL-17 antagonist (PN-881), an oral hepcidin functional mimetic (PN-8047), and obesity dual and triple agonists such as PN-477, most still in early stages.

The investment picture is a partnered-biotech royalty-and-milestone model rather than a self-commercializing drug company. Protagonist collects upfront payments, development and approval milestones, and tiered royalties from J&J and Takeda instead of running its own sales force, which lowers commercial risk but also caps direct upside and leaves it dependent on partner execution. In the first quarter of 2026 the company reported roughly $56.4 million of license and collaboration revenue and a small net profit, helped by a $50 million ICOTYDE approval milestone. The second quarter was far larger: about $213.5 million of revenue and $162.9 million of net income, with EPS of $2.29 against a $1.93 consensus, as Takeda's initial $200 million rusfertide opt-out payment came in. The third quarter, reported November 5, 2026, was larger again: about $274.4 million of revenue, of which about $266.6 million was recognition of the $275 million Takeda owed for the second $200 million opt-out fee and the $75 million MIMRYLO approval milestone, and net income of about $220.0 million, or $3.07 per diluted share against a $2.66 consensus. Nine-month net income reached about $386.6 million. Cash, cash equivalents and marketable securities were about $834.6 million at September 30, 2026, up from about $646.0 million at the end of 2025. Trailing twelve-month revenue is about $552 million and net income about $342 million. In September the board authorized up to $300 million of share repurchases. The stock, at a market cap of about $8.0 billion and about $121.85 a share on November 20, 2026, still prices in a lot of future royalty value that has yet to be earned, and analysts expect revenue to fall back to about $236 million in 2027 once the one-time payments roll off, with Q4 2026 expected to show a small loss.

What's driving Protagonist Therapeutics, Inc. (PTGX)?

1. Icotrokinra (ICOTYDE) launch with J&J

Icotrokinra is the first oral peptide that blocks the IL-23 receptor and was approved by the FDA in March 2026 for moderate-to-severe plaque psoriasis, launching with Johnson & Johnson as the commercial partner. Protagonist earned a $50 million approval milestone and is eligible for up to roughly $580 million in additional milestones plus tiered royalties of about 6% to 10%. ICOTYDE is now also approved in China, Japan and the EU for psoriasis, two-year Phase 3 results (ICONIC-TOTAL and ICONIC-LEAD) have been presented, and the Phase 2 ANTHEM-UC results in ulcerative colitis were published in the New England Journal of Medicine on October 14, 2026. Programs in psoriatic arthritis, ulcerative colitis, and Crohn's disease could widen the addressable market over time. Protagonist has not yet disclosed royalty revenue from ICOTYDE sales.

2. MIMRYLO (rusfertide) launch with Takeda

Rusfertide, a hepcidin mimetic for polycythemia vera, was approved by the FDA in August 2026 as MIMRYLO, based mainly on the Phase 3 VERIFY study that more than doubled clinical response rates. Protagonist exercised its U.S. opt-out right under the Takeda collaboration in April 2026, which brought a $200 million payment in Q2, a further $200 million opt-out fee plus a $75 million approval milestone earned in August, and tiered royalties of 14% to 29% on worldwide net sales (a weighted average near 21%, with the top tier above $1.5 billion of annual sales), plus up to $875 million of additional milestones. Takeda now controls pricing, market access and launch sequencing.

3. Milestone and royalty cash flows

Because both lead assets are partnered, Protagonist's revenue is a stream of approval milestones, opt-out payments, sales milestones, and tiered royalties rather than product sales. This model produced profits in each of the first three quarters of 2026, including about $220.0 million of net income in Q3, and a cash and securities balance of about $834.6 million at September 30. With little debt (about $9 million), the board authorized a $300 million share repurchase in September 2026, to be funded from cash, securities and collaboration royalties and payments; the Q3 release did not say how much has been bought. The open question is the gap after these one-time payments: consensus expects a small loss in Q4 2026 and 2027 EPS of only about $0.35 until royalties scale, and the company expects R&D spending to rise for the rest of 2026.

4. Wholly owned pipeline optionality

Beyond the two partnered drugs, Protagonist is advancing PN-881, an oral IL-17 peptide antagonist that has completed Phase 1, with a Phase 2b dose-ranging study in plaque psoriasis planned for early Q1 2027; PN-8047, an oral hepcidin functional mimetic, with Phase 1 expected in Q1 2027; and obesity dual and triple GLP/GIP/GCG agonists, prioritizing oral PN-477o (Phase 1 expected in the first half of 2027) followed by PN-458o (second half of 2027). These programs are unpartnered today, giving the company potential to retain more economics or strike future deals if data reads out well.

What are the risks to Protagonist Therapeutics, Inc. (PTGX)?

As a partner-dependent biotech, Protagonist has limited control over commercial execution: ICOTYDE's uptake and MIMRYLO's launch sit largely with J&J and Takeda, and Protagonist no longer controls MIMRYLO's pricing, market access or commercial investment. Slow psoriasis or polycythemia vera launch traction, weak payer access, or disappointing later-stage data in psoriatic arthritis or inflammatory bowel disease could remove large chunks of the royalty value the stock currently prices in. Much of 2026's revenue is lumpy, one-time milestone and opt-out income, so analysts expect revenue to drop to about $236 million and EPS to about $0.35 in 2027, with a small loss expected in Q4 2026. The early pipeline, including obesity agonists, is unproven and competes against far larger, better-funded programs. An insider sold about $18.2 million of shares in September 2026, per an SEC filing. Valuation near an $8.0 billion market cap, roughly 14x trailing revenue and about 350x 2027 consensus earnings, already embeds substantial future success, and the shares are about 24% below their 52-week high of $160.81 after falling about 12% in the month to November 20, 2026, a reminder of how sharply they can move.

What is the Protagonist Therapeutics, Inc. (PTGX) forecast?

14 analysts publish price targets on PTGX, averaging $182.36 as of November 2026, or +50.2% against the $121.40 share price on November 20, 2026. The published targets run from $151.00 to $225.00, a moderate spread, and the ratings split 14 buy, 0 hold, 0 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PTGX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is PTGX a buy or a sell?

We give no verdict on Protagonist Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Icotrokinra (ICOTYDE) launch with J&J. Icotrokinra is the first oral peptide that blocks the IL-23 receptor and was approved by the FDA in March 2026 for moderate-to-severe plaque psoriasis, launching with Johnson & Johnson as the commercial partner. The most optimistic published target, $225.00, assumes this works close to its best case.

The case against. As a partner-dependent biotech, Protagonist has limited control over commercial execution: ICOTYDE's uptake and MIMRYLO's launch sit largely with J&J and Takeda, and Protagonist no longer controls MIMRYLO's pricing, market access or commercial investment. The most pessimistic target, $151.00, is roughly what PTGX is worth if this bites instead.

Read the full bull and bear case on PTGX, including what would have to change to break either one. Walnut is not an investment adviser.

Has Protagonist Therapeutics, Inc. (PTGX) split its stock?

No. Protagonist Therapeutics, Inc. (PTGX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Protagonist Therapeutics, Inc. (PTGX) valued?

Market cap, P/E and dividend yield at today's price are in the PTGX key stats above. The business figures below come from Protagonist Therapeutics, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$552M
  • Q3 2026 revenue: ~$274.4M (~$266.6M from the Takeda opt-out fee and MIMRYLO milestone)
  • Q3 2026 net income / EPS: ~$220.0M / $3.07 (vs ~$2.66 consensus)
  • Net income (TTM): ~$342M (trailing P/E ~26x)
  • Cash and marketable securities: ~$835M at September 30, 2026; debt ~$9M
  • Analyst mean target: ~$182 (14 analysts, consensus Strong Buy)

As of November 2026: As of November 2026, revenue is dominated by milestone and collaboration payments, including Takeda's $200 million initial opt-out payment in Q2 and the further $200 million opt-out fee plus $75 million MIMRYLO approval milestone recognized mostly in Q3. That lifted trailing twelve-month net income to about $342 million and the trailing P/E to a modest-looking 26x, but consensus sees 2027 revenue near $236 million and EPS of only about $0.35, which is why the forward P/E of about 350x says little either. The valuation is really a bet on the royalty streams from ICOTYDE and MIMRYLO; the average analyst target is about $182 (14 analysts), and UBS initiated at Buy with a $184 target in October 2026.

Which ETFs hold Protagonist Therapeutics, Inc. (PTGX)?

If you want PTGX exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in PTGXExpense ratio
IJRiShares Core S&P Small-Cap ETF0.53%0.06%
SPSMState Street SPDR Portfolio S&P 600 Small Cap ETF0.53%0.03%
IWOiShares Russell 2000 Growth ETF0.60%0.24%
IJTiShares S&P Small-Cap 600 Growth ETF1.1%0.18%
VIOOVanguard S&P Small-Cap 600 Index Fund ETF Shares0.5%0.07%
SLYGState Street SPDR S&P 600 Small Cap Growth ETF1.1%0.15%

Who competes with Protagonist Therapeutics, Inc. (PTGX)?

Oral IL-23 and psoriasis therapies

Icotrokinra competes for psoriasis and inflammatory-bowel-disease share against injectable IL-23 biologics like AbbVie's Skyrizi and Johnson & Johnson's own Tremfya, and oral options such as Bristol Myers Squibb's Sotyktu (deucravacitinib). The pitch is a convenient once-daily oral peptide, but the category is crowded and dominated by large players with deep sales reach.

Polycythemia vera and hematology drugs

Rusfertide targets polycythemia vera, where current management includes phlebotomy plus agents like hydroxyurea, interferons, and PharmaEssentia's Besremi, and where other hepcidin-pathway and myeloproliferative-disease programs are in development. Rusfertide's differentiation is a peptide that controls red-blood-cell production, but adoption depends on how it fits alongside established standards of care.

Peptide-focused and obesity-agonist biotechs

Protagonist's platform and its earlier obesity dual and triple agonists compete with a wide field of metabolic and peptide-drug developers, including the GLP-1 leaders Eli Lilly and Novo Nordisk and numerous smaller obesity biotechs. These programs are early and unproven relative to entrenched incumbents with far larger budgets.

What stocks are similar to Protagonist Therapeutics, Inc. (PTGX)?

Other names that sit close to PTGX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Protagonist Therapeutics, Inc. (PTGX)

There are three common ways to get PTGX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (IJR, SPSM, IWO), which spreads the position across many companies. Or build it into a focused thematic portfolio, so PTGX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PTGX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Protagonist Therapeutics, Inc. (PTGX)

PTGX is a partner-driven biotech royalty story on two approved peptides, with large milestone payments turning it solidly profitable in 2026 (about $387 million of net income in the first nine months) and a $300 million buyback authorized, but with valuation (about $8.0 billion) now tied to how fast ICOTYDE and MIMRYLO sales, and the royalties on them, actually grow once those one-time payments end.

More on Protagonist Therapeutics, Inc. (PTGX)

Whether PTGX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PTGX a buy or a sell?, and where the stock could go from here in the PTGX stock forecast.

For income investors, whether PTGX pays a dividend and how the payout looks is covered in does PTGX pay a dividend? And to weigh PTGX against a peer, read the full side-by-side comparisons: PTGX vs ABBV and PTGX vs JNJ.

Wondering how PTGX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Protagonist Therapeutics, Inc.

Ask Walnut's AI anything about PTGX and see how it fits what you own.

FAQ

What does Protagonist Therapeutics do?

+

It is a commercial-stage biotech that discovers peptide-based drugs and develops them largely through partners. Its two lead assets, both FDA-approved in 2026, are icotrokinra (ICOTYDE) for psoriasis, partnered with Johnson & Johnson, and rusfertide (MIMRYLO) for polycythemia vera, partnered with Takeda.

How does PTGX make money?

+

Primarily through its partnerships: upfront and opt-out payments, development and approval milestones, sales milestones, and tiered royalties from J&J and Takeda. It does not run its own commercial sales force for its lead drugs, so revenue is lumpy and event-driven rather than steady product sales.

What is icotrokinra (ICOTYDE)?

+

Icotrokinra is an oral peptide that blocks the IL-23 receptor, licensed to Johnson & Johnson and marketed as ICOTYDE. The FDA approved it in March 2026 for moderate-to-severe plaque psoriasis, and it has since been approved in China, Japan and the EU for psoriasis. It is in development for psoriatic arthritis, ulcerative colitis, and Crohn's disease.

What is rusfertide and when is its FDA decision?

+

Rusfertide is a once-weekly injectable hepcidin mimetic peptide for polycythemia vera, licensed to Takeda. The FDA approved it in August 2026 as MIMRYLO for erythrocytosis in adults with polycythemia vera, based mainly on the Phase 3 VERIFY study. Approval triggered a $75 million milestone, and Protagonist receives tiered royalties of 14% to 29% on worldwide net sales.

Is PTGX profitable?

+

Yes, in 2026 so far. It reported net income of about $3.8 million in the first quarter, about $162.9 million in the second and about $220.0 million in the third, for about $386.6 million over nine months and trailing twelve-month net income of about $342 million. That was driven by one-time milestone and opt-out payments from Takeda and J&J, and analysts expect a small loss in Q4 2026 and EPS of only about $0.35 in 2027 once those roll off, so profitability is not yet recurring.

How much cash does Protagonist have?

+

Cash, cash equivalents, and marketable securities totaled about $834.6 million as of September 30, 2026, up from about $646.0 million at the end of 2025. The Q3 figure reflects the $275 million Takeda owed for the second opt-out fee and the MIMRYLO approval milestone. Debt is minimal (about $9 million), and in September 2026 the board authorized up to $300 million of share repurchases.

What are the main risks for PTGX investors?

+

Key risks include slow ICOTYDE or MIMRYLO launch uptake, dependence on partners J&J and Takeda for execution and pricing, lumpy milestone-based revenue that is expected to shrink in 2027, an unproven early pipeline, and a valuation near $8.0 billion that already prices in a lot of future success. Walnut is not an investment adviser.

Who are Protagonist's main competitors?

+

In psoriasis and inflammatory bowel disease, icotrokinra competes with IL-23 biologics like Skyrizi and Tremfya and oral drugs like Sotyktu. In polycythemia vera, rusfertide competes with standards of care and drugs like Besremi. Its obesity agonists face GLP-1 leaders Eli Lilly and Novo Nordisk.

How did Protagonist do in its latest quarter?

+

In Q3 2026 (reported November 5) Protagonist reported revenue of about $274.4 million and net income of about $220.0 million, or $3.07 per diluted share against a $2.66 consensus. About $266.6 million of the revenue was recognition of the $275 million from Takeda for the second opt-out fee and the MIMRYLO approval milestone, and the release did not break out royalties. Cash and securities stood at about $834.6 million. For Q4 2026 analysts expect a loss of about $0.20 per share on about $50 million of revenue.

How has PTGX stock performed in 2026?

+

Well for the year, with a pullback since the summer. As of November 20, 2026 PTGX closed near $121.85, up about 40% year to date and 45% over one year, though down about 12% over the past month and 19% over three months, and below its 52-week high of $160.81 (the low was $77.00). The gains followed the ICOTYDE approval in March and the MIMRYLO approval in August. Past performance does not predict future returns.

Does Protagonist buy back stock or pay a dividend?

+

Protagonist pays no dividend. On September 8, 2026 its board authorized repurchases of up to $300 million of common stock, funded from cash and from royalties and payments under the Takeda and J&J collaborations. The program has no stated end date and may be modified or suspended at any time.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Protagonist Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.